Synopsys news12/28/2022 According to data from MarketBeat, Medtronic currently has an average rating of Buy and a consensus price target of $139.30. Six investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Finally, Truist Securities decreased their price objective on Medtronic from $148.00 to $142.00 and set a buy rating for the company in a research note on Wednesday, November 24th. Zacks Investment Research upgraded Medtronic from a sell rating to a hold rating and set a $121.00 price objective for the company in a research note on Friday, November 26th. Synopsys 3DIC Compiler Qualified for Samsung Foundrys Multi-Die Integration Flow, Accelerating 2.5D and 3D Designs MOUNTAIN VIEW, Calif., Nov. UBS Group lifted their price objective on Medtronic from $145.00 to $149.00 and gave the company a buy rating in a research note on Wednesday, August 25th. Piper Sandler reiterated an overweight rating and issued a $152.00 price objective (up previously from $140.00) on shares of Medtronic in a research note on Tuesday, August 24th. Morgan Stanley decreased their price objective on Medtronic from $154.00 to $145.00 and set an overweight rating for the company in a research note on Wednesday, November 24th. One way to double-check a companys growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. Thats a 19 gain respectable growth in the broader scheme of things. Several other equities analysts have also recently issued reports on the company. Synopsys boosted its trailing twelve month EPS from US4.17 to US4.94, in the last year.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |